Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Vaxil Bio ( (TSE:VXL) ) is now available.
Vaxil Bio Ltd. announced that Daniel Bloch has joined its audit committee, and the company will resume stock trading on April 7, 2025. However, the TSX Venture Exchange has placed Vaxil on a 90-day notice for potential transfer to the NEX board. In a strategic move to conserve cash, Vaxil will close its Israeli subsidiaries and cease renewing core patents. The company is also exploring other strategic options to maximize shareholder value, including the potential discontinuation of ImMucin™ development.
More about Vaxil Bio
Vaxil Bio Ltd. is an Israeli immunotherapy biotech company focused on developing novel treatments targeting prominent cancer markers and infectious diseases. Its lead product, ImMucin™, has completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA.
Technical Sentiment Signal: Buy
Current Market Cap: C$684.9K
For an in-depth examination of VXL stock, go to TipRanks’ Stock Analysis page.